Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity

  • Jahae Kim
  • Sang-Geon Cho
  • Sae-Ryung Kang
  • Su Woong Yoo
  • Seong Young Kwon
  • Jung-Joon Min
  • Hee-Seung Bom
  • Ho-Chun SongEmail author
Original Article



The aim of this study was to investigate changes in myocardial uptake evaluated by oncologic 18F-fluorodeoxyglucose (FDG) PET/CT scans and to determine the relationship between myocardial FDG uptake and cancer therapy-induced cardiotoxicity in breast cancer patients who underwent anthracycline or trastuzumab.


We reviewed 121 consecutive patients who underwent oncologic FDG PET/CT and echocardiography at baseline and post-therapy with anthracyclines or trastuzumab for breast cancer. Grade in LV wall, uptake pattern in LV wall, and the presence of RV wall uptake were assessed by visual analysis, and the mean SUV in the LV and RV walls and the change of SUV (ΔSUV) between baseline and post-therapy PET/CT were measured by quantitative analysis. Multiple logistic regression analyses were performed to evaluate the association between PET parameters and cardiotoxicity.


Fifteen patients (12%) showed cardiotoxicity after therapy. The cardiotoxic group tended to show more diffuse LV uptake, higher SUV, and ΔSUV of RV wall than the non-cardiotoxic group following therapy with anthracyclines or trastuzumab. Logistic regression analysis showed that the presence of RV wall uptake, SUV of RV wall (> 1.8), and ΔSUV of RV wall (> 0.4) were significantly associated with cardiotoxicity after controlling for age, radiotherapy, and treatment.


The presence of RV wall uptake and the increase of SUV of RV wall on post-therapy PET/CT were associated with cardiotoxicity in breast cancer patients who underwent anthracycline or trastuzumab. Oncologic FDG PET/CT scans can provide information regarding cancer therapy-induced cardiotoxicity as well as tumor response.


Diagnostic and prognostic application image interpretation PET 



Positron emission tomography


Computed tomography


Left ventricular


Right ventricular


Standardized uptake value


Left ventricular ejection fraction



This study was supported by a grant (CRI17017-1) from Chonnam National University Hospital Biomedical Research Institute. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


JK’s work has been funded by a grant (CRI17017-1) from Chonnam National University Hospital Biomedical Research Institute. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All other authors declared no potential conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

This retrospective study was approved by the institutional ethics committee, and the requirement to obtain informed consent was waived.

Supplementary material

12350_2019_1617_MOESM1_ESM.pptx (46 kb)
Electronic supplementary material 1 (PPTX 47 kb)
12350_2019_1617_MOESM2_ESM.pptx (1.5 mb)
Electronic supplementary material 2 (PPTX 1490 kb)


  1. 1.
    Santoni M, Guerra F, Conti A, Lucarelli A, Rinaldi S, Belvederesi L, et al. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. Cancer Treat Rev 2017;59:123-31.CrossRefGoogle Scholar
  2. 2.
    Lorenzini C, Lamberti C, Aquilina M, Rocca A, Cortesi P, Corsi C. Reliability of left ventricular ejection fraction from three-dimensional echocardiography for cardiotoxicity onset detection in patients with breast cancer. J Am Soc Echocardiogr 2017;30:1103-10.CrossRefGoogle Scholar
  3. 3.
    Ku CR, Lee N, Hong JW, Kwon IG, Hyung WJ, Noh SH, et al. Intestinal glycolysis visualized by FDG PET/CT correlates with glucose decrement after gastrectomy. Diabetes 2017;66:385-91.CrossRefGoogle Scholar
  4. 4.
    Atterton-Evans V, Turner J, Vivanti A, Robertson T. Variances of dietary preparation for suppression of physiological 18F-FDG myocardial uptake in the presence of cardiac sarcoidosis: A systematic review. J Nucl Cardiol 2018. Scholar
  5. 5.
    Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, et al. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14). Eur J Cancer 2016;58:112-21.CrossRefGoogle Scholar
  6. 6.
    Felix RCM, Gouvea CM, Reis CCW, dos Santos Miranda JS, Schtruk LBCE, Colafranceschi AS, et al. 18F-fluorodeoxyglucose use after cardiac transplant: A comparative study of suppression of physiological myocardial uptake. J Nucl Cardiol 2018. Scholar
  7. 7.
    Dou K-F, Gao X-J, Xie B-Q, Li Y, He Z-X, Yang M-F. Dual-time-point myocardial 18 F-FDG imaging in the detection of coronary artery disease. BMC Cardiovasc Disorder 2017;17:120.CrossRefGoogle Scholar
  8. 8.
    Bauckneht M, Ferrarazzo G, Fiz F, Morbelli S, Sarocchi M, Pastorino F, et al. Doxorubicin effect on myocardial metabolism as a pre-requisite for subsequent development of cardiac toxicity: A translational 18F-FDG PET/CT observation. J Nucl Med 2017;58:1638-45.CrossRefGoogle Scholar
  9. 9.
    Gorla AK, Sood A, Prakash G, Parmar M, Mittal BR. Substantial increase in myocardial FDG uptake on interim PET/CT may be an early sign of adriamycin-induced cardiotoxicity. Clin Nucl Med 2016;41:462-3.CrossRefGoogle Scholar
  10. 10.
    Borde C, Kand P, Basu S. Enhanced myocardial fluorodeoxyglucose uptake following adriamycin-based therapy: Evidence of early chemotherapeutic cardiotoxicity? World J Radiol 2012;4:220-3.CrossRefGoogle Scholar
  11. 11.
    Murtagh G, Lyons T, O’Connell E, Ballot J, Geraghty L, Fennelly D, et al. Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up. Breast Cancer Res Treat 2016;156:501-6.CrossRefGoogle Scholar
  12. 12.
    Boyd A, Stoodley P, Richards D, Hui R, Harnett P, Vo K, et al. Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. PLoS ONE 2017;12:e0175544.CrossRefGoogle Scholar
  13. 13.
    Friedberg MK. Imaging right-left ventricular interactions. Cardiovasc Imaging 2018;11:755-71.CrossRefGoogle Scholar
  14. 14.
    Wang L, Ma X, Xiang L, Lu M, Yan C, Zhao S, et al. The characterization and prognostic significance of right ventricular glucose metabolism in non-ischemic dilated cardiomyopathy. J Nucl Cardiol 2016;23:758-67.CrossRefGoogle Scholar
  15. 15.
    Kadkhodayan A, Chareonthaitawee P, Raman SV, Cooper LT. Imaging of inflammation in unexplained cardiomyopathy. Cardiovasc Imaging 2016;9:603-17.Google Scholar
  16. 16.
    Betancourt CSL, Palacio D, Benveniste MF, Carter BW, Gladish G. Pitfalls and misinterpretations of cardiac findings on PET/CT imaging: A careful look at the heart in oncology patients. Curr Probl Diagn Radiol 2018;5:4. Scholar
  17. 17.
    Saygin D, Highland KB, Farha S, Park M, Sharp J, Roach EC, et al. Metabolic and functional evaluation of the heart and lungs in pulmonary hypertension by gated 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Pulm Circ 2017;7:428-38.CrossRefGoogle Scholar
  18. 18.
    Yarana C, Carroll D, Chen J, Chaiswing L, Zhao Y, Noel T, et al. Extracellular vesicles released by cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac injury. Clin Cancer Res 2018;24:1644-53.CrossRefGoogle Scholar
  19. 19.
    Goyal SN, Mahajan UB, Chandrayan G, Kumawat VS, Kamble S, Patil P, et al. Protective effect of oleanolic acid on oxidative injury and cellular abnormalities in doxorubicin induced cardiac toxicity in rats. Am J Transl Res 2016;8:60-9.Google Scholar
  20. 20.
    Ghigo A, Li M, Hirsch E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochim et Biophys Acta 2016;1863:1916-25.CrossRefGoogle Scholar
  21. 21.
    Lu Y, Grant C, Xie K, Sweiss NJ. Suppression of myocardial 18F-FDG uptake through prolonged high-fat, high-protein, and very-low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. Clin Nucl Med 2017;42:88-94.CrossRefGoogle Scholar
  22. 22.
    Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol 2016;23:244-52.CrossRefGoogle Scholar
  23. 23.
    Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, et al. Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Med 2017;58:1341-53.CrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2019

Authors and Affiliations

  • Jahae Kim
    • 1
  • Sang-Geon Cho
    • 1
  • Sae-Ryung Kang
    • 2
  • Su Woong Yoo
    • 2
  • Seong Young Kwon
    • 2
  • Jung-Joon Min
    • 2
  • Hee-Seung Bom
    • 2
  • Ho-Chun Song
    • 1
    • 3
    Email author
  1. 1.Department of Nuclear MedicineChonnam National University HospitalGwangjuSouth Korea
  2. 2.Department of Nuclear MedicineChonnam National University Hwasun HospitalHwasunSouth Korea
  3. 3.Department of Nuclear MedicineChonnam National University Hospital and Medical SchoolDonggu, GwangjuRepublic of Korea

Personalised recommendations